Mount Sinai researchers develop novel therapy that could be effective in many cancers
(Press-News.org) New York, NY (July 23, 2021) -- Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
The therapy is an engineered molecule, named MS21, that causes the degradation of AKT, an enzyme that is overly active in many cancers. This study laid out evidence that pharmacological degradation of AKT is a viable treatment for cancers with mutations in certain genes.
AKT is a cancer gene that encodes an enzyme that is frequently abnormally activated in cancer cells to stimulate tumor growth. Degradation of AKT reverses these processes and inhibits tumor growth.
"Our study lays a solid foundation for the clinical development of an AKT degrader for the treatment of human cancers with certain gene mutations," said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute and Ward-Coleman Chair in Cancer Research and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. "Examination of 44,000 human cancers identified that 19 percent of tumors have at least one of these mutations, suggesting that a large population of cancer patients could benefit from therapy with an AKT degrader such as MS21."
MS21 was tested in human cancer-derived cell lines, which are models used in laboratories to study the efficacy of cancer therapies. Mount Sinai is looking to develop MS21 with an industry partner to open clinical trials for patients.
"Translating these findings into effective cancer therapies for patients is a high priority because the mutations and the resulting cancer-driving pathways that we lay out in this study are arguably the most commonly activated pathways in human cancer, but this effort has proven to be particularly challenging," said Jian Jin, PhD, Mount Sinai Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery at Icahn Mount Sinai. "We look forward to an opportunity to develop this molecule into a therapy that is ready to be studied in clinical trials."
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care--from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
ELSE PRESS RELEASES FROM THIS DATE:
Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.
An international team used mass cytometry - an in-depth way of characterising individual cells - and machine learning to discover 'immune signatures' associated with symptomatic or asymptomatic infections in people infected with the Plasmodium vivax parasite. This uncovered an unexpected role for immune T cells in protection against malaria, ...
How does a view of nature gain its gloss of beauty? We know that the sight of beautiful landscapes engages the brain's reward systems. But how does the brain transform visual signals into aesthetic ones? Why do we perceive a mountain vista or passing clouds as beautiful? A research team from the Max Planck Institute for Empirical Aesthetics has taken up this question and investigated how our brains proceed from merely seeing a landscape to feeling its aesthetic impact.
In their study, the research team presented artistic landscape videos to 24 participants. Using functional magnetic resonance imaging (fMRI), they measured the participants' brain activity as they viewed and rated the videos. Their findings have just been published in the ...
As Xi'an Jiaotong-Liverpool University researchers completed their research on coloured architectural concrete, they found a surprising result--green pigmented cement had impurities that produced porous, poor quality concrete. Meanwhile, red and blue pigments had little effect.
The research was conducted by Mehreen Heerah, a graduate of XJTLU's Department of Civil Engineering, Dr Graham Dawson of XJTLU's Department of Chemistry, and Isaac Galobardes of Mohammed VI Polytechnic University.
Pigmented architectural concrete is used as a visually appealing alternative to grey concrete, such as in Barcelona's Ciutat de la Justícia, explains Dr Dawson. As the demand for pigmented architectural concrete grows, so does the importance of this research.
Not easy ...
New research from the University of Otago debunks a long-held belief about our ancestors' eating habits.
For more than 60 years, researchers have believed Paranthropus, a close fossil relative of ours which lived about one to three million years ago, evolved massive back teeth to consume hard food items such as seeds and nuts, while our own direct ancestors, the genus Homo, is thought to have evolved smaller teeth due to eating softer food such as cooked food and meats.
However, after travelling to several large institutes and museums in South Africa, Japan and the ...
About six gigatons -- roughly 12 times the mass of all living humans -- of carbon appears to be emitted over land every year, according to data from the Chinese Global Carbon Dioxide Monitoring Scientific Experimental Satellite (TanSat).
Using data on how carbon mixes with dry air collected from May 2017 to April 2018, researchers developed the first global carbon flux dataset and map. They published their results in Advances in Atmospheric Sciences.
The map was developed by applying TanSat's satellite observations to models of how greenhouse gasses are exchanged among Earth's atmosphere, land, ...
Reston, VA--A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of the Journal of Nuclear Medicine.
All cancer cells have an insatiable appetite for iron, which provides them the energy they need to multiply. As a result, tumors have higher levels of iron than normal tissues. Recent advances in chemistry have led scientists to take advantage of this altered state, targeting the expanded cytosolic ...
MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology.
Brian Hess, M.D., a Hollings researcher and lymphoma specialist at MUSC Health, was instrumental in bringing the phase 2 trial to Hollings. The manufacturer of Loncastuximab tesirine, ADC Therapeutics S.A., sponsored the trial.
B-cell non-Hodgkin lymphoma (NHL) is a blood cancer that begins in the lymph nodes, spleen or bone marrow. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive NHL. New treatment options are vital for patients with DLBCL. ...
Due to the global efforts to meet sustainability standards, many countries are currently looking to replace concrete with wood in buildings. France, for example, will require that all new public buildings will be made from at least 50 percent wood or other sustainable materials starting in 2022.
Because wood is prone to degradation when exposed to sunlight and moisture, protective coatings can help bring wood into wider use. Researchers at Aalto University have used lignin, a natural polymer abundant in wood and other plant sources, to create a safe, low-cost and high-performing coating for use in construction.
'Our new coating has great potential to ...
A new optogenetic tool, a protein that can be controlled by light, has been characterized by researchers at Ruhr-Universität Bochum (RUB). They used an opsin - a protein that occurs in the brain and eyes - from zebrafish and introduced it into the brain of mice. Unlike other optogenetic tools, this opsin is not switched on but rather switched off by light. Experiments also showed that the tool could be suitable for investigating changes in the brain that are responsible for the development of epilepsy.
The teams led by Professor Melanie Mark from the Behavioural Neurobiology Research Group and Professor Stefan Herlitze from the Department ...
As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus. Vaccines against COVID-19, which were developed based on the chemistry and genetic code of this initial virus, may confer less protection if the antibodies they help people produce do not fend off new viral strains. Now, researchers from Brigham and Women's Hospital and collaborators have created an "atlas" that charts how 152 different antibodies attack a major ...
LAST 30 PRESS RELEASES:
[Press-News.org] Mount Sinai researchers develop novel therapy that could be effective in many cancers